Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
Stammdaten
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Viking Therapeutics, Inc. |
|---|---|
| Ticker | VKTX |
| CIK | 0001607678 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,81 Mrd. USD |
| Beta | 0,82 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -359,639,000 | -3.19 | 715,729,000 | 639,062,000 |
| 2025-09-30 | 10-Q | 0 | -90,787,000 | -0.81 | 739,415,000 | 713,030,000 |
| 2025-06-30 | 10-Q | 0 | -65,561,000 | -0.58 | 827,851,000 | 795,461,000 |
| 2025-03-31 | 10-Q | 0 | -45,629,000 | -0.41 | 866,993,000 | 846,918,000 |
| 2024-12-31 | 10-K | 0 | -109,963,000 | -1.01 | 908,321,000 | 880,278,000 |
| 2024-09-30 | 10-Q | 0 | -24,940,000 | -0.22 | 937,888,000 | 911,448,000 |
| 2024-06-30 | 10-Q | 0 | -22,250,000 | -0.20 | 946,839,000 | 920,980,000 |
| 2024-03-31 | 10-Q | 0 | -27,356,000 | -0.26 | 967,518,000 | 933,892,000 |
| 2023-12-31 | 10-K | 0 | -85,895,000 | -0.91 | 368,490,000 | 348,419,000 |
| 2023-09-30 | 10-Q | 0 | -22,534,000 | -0.23 | 382,663,000 | 368,240,000 |
| 2023-06-30 | 10-Q | 0 | -19,225,000 | -0.19 | 400,693,000 | 386,115,000 |
| 2023-03-31 | 10-Q | 0 | -19,531,000 | -0.25 | 150,895,000 | 134,065,000 |
| 2022-12-31 | 10-K | 0 | -68,867,000 | -0.90 | 168,529,000 | 145,322,000 |
| 2022-09-30 | 10-Q | 0 | -15,773,000 | -0.21 | 166,683,000 | 151,285,000 |
| 2022-06-30 | 10-Q | 0 | -17,432,000 | -0.23 | 181,508,000 | 165,230,000 |
| 2022-03-31 | 10-Q | 0 | -16,103,000 | -0.21 | 195,028,000 | 182,270,000 |
| 2021-12-31 | 10-K | 0 | -54,990,000 | -0.71 | 210,662,000 | 201,884,000 |
| 2021-09-30 | 10-Q | 0 | -13,243,000 | -0.17 | 224,474,000 | 213,121,000 |
| 2021-06-30 | 10-Q | 0 | -15,381,000 | -0.20 | 237,845,000 | 224,974,000 |
| 2021-03-31 | 10-Q | 0 | -14,010,000 | 250,139,000 | 237,223,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -41,276 | 34.22 | -1,412,398.68 | -90,4% | |
| 2026-01-05 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -132,454 | 32.29 | -4,277,032.38 | -273,7% | |
| 2026-01-05 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -53,279 | 33.38 | -1,778,266.54 | -113,8% | |
| 2026-01-05 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -6,400 | 35.07 | -224,423.04 | -14,4% | |
| 2026-01-02 | FOEHR MATTHEW W | Director | Open Market Sale | -16,000 | 35.11 | -561,694.40 | -35,9% | |
| 2025-10-28 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -38,989 | 35.01 | -1,364,923.01 | -87,4% | |
| 2025-10-27 | Rowland Charles A Jr | Director | Open Market Sale | -60,000 | 35.57 | -2,134,278.00 | -136,6% | |
| 2025-07-03 | Lian Brian | Director, Officer, President & CEO | Open Market Sale | -26,889 | 27.80 | -747,632.51 | -47,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.